Luo ilmainen tili jotta voit seurata yrityksiä, osallistua foorumin keskusteluun sekä kommentoida meidän sisältöä. Valitse sinulle sopivin tili.
Oliko sinulla jo tili?
Follow this company like 1458 other investors.
Redeye returns with a follow-up note to Genovis’ Q1’22 report. We are encouraged to see that the company is reporting yet another solid quarter and that the growth remains high, particularly in the Enzyme business.
Redeye regards Genovis’ Q1’22 report as solid and is encouraged to see continuously strong growth in the Enzyme business.
Top Picks increases one of its largest positions even further, following solid operational development and a falling stock price. Our cash position will be about 9% after the transaction. Top Picks is a model portfolio by Redeye.
Redeye returns with a follow-up note to Genovis’ Q4’21 report. We are encouraged to see that Genovis is returning with higher growth and believe that the company has strong growth prospects in 2022 and onwards.
Redeye shares its initial take on Genovis’ Q4´21 report.
Redeye returns with a follow up-note to Genovis’ Q3’21 report. We believe that the third quarter is just a bump in the road and continue to have a very positive long-term view.
Redeye provides an initial take on Genovis’ Q3 report. We argue that it is a relatively weak report as the sales growth was only 10% (low for Genovis). However, the third quarter is a seasonally weaker quarter for the company.
Redeye returns with an update following Genovis’ licensing deal with Selecta Biosciences – adeal that clearly validates the huge potential in the company and its SmartEnzymes.
Redeye provides a first comment on today’s news regarding the strategic licensing deal with Selecta Bioscience.
Redeye gives a short comment on today’s announcement that Genovis has hired Magnus Långberg as the new CFO of the Group.